Marshall University: First FDA-Approved RSV Vaccine Available for Pregnant Patients at Marshall Health
September 08, 2023
September 08, 2023
HUNTINGTON, West Virginia, Sept. 8 -- Marshall University issued the following news release:
Pfizer's FDA-approved ABRYSVO(TM) vaccine for the prevention of respiratory syncytial virus (RSV) in infants through the immunization of pregnant patients at 32 to 36 weeks is available at Marshall OB/GYN.
ABRYSVO is the first and only U.S.-approved maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease (LRTD) and s . . .
Pfizer's FDA-approved ABRYSVO(TM) vaccine for the prevention of respiratory syncytial virus (RSV) in infants through the immunization of pregnant patients at 32 to 36 weeks is available at Marshall OB/GYN.
ABRYSVO is the first and only U.S.-approved maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease (LRTD) and s . . .